Hetrombopag for low platelets before surgery
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether the drug hetrombopag can safely raise platelet counts in people with immune thrombocytopenia (ITP) before they have surgery. The goal is to reduce bleeding risk during and after the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have immune thrombocytopenia (ITP), which is a condition that causes low platelets.
- Your platelet count must be 75 or lower before a planned surgery (not an emergency).
- You cannot have had a serious allergic reaction to TPO-RA drugs like hetrombopag.
- You must not currently have severe bleeding (like bleeding in the stomach, brain, or other organs) or a blood clotting disorder.
- You cannot be pregnant, breastfeeding, or have certain serious heart conditions or recent heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two medications (lusutrombopag and recombinant human thrombopoietin) given together to raise platelet levels before a planned surgery in people with chronic liver disease. The goal is to reduce the need for platelet transfusions and make the procedure safer.
This trial tests a drug called avatrombopag (a pill) to help raise platelet counts in people who develop very low platelets after a stem cell transplant from a half-matched donor (haplo-HSCT). It aims to see if the drug is safe and effective at reducing the need for platelet transfusions.
This study tests whether a drug called hetrombopag can help your immune system stop attacking your platelets, so your platelet count stays up even after stopping the drug. It's for people with ITP who responded well to hetrombopag but want to see if they can stay in remission without it.
This study tests if a combination of two medications, hetrombopag (a pill) and rhTPO (an injection), can safely raise very low platelet counts in people with solid tumors caused by their cancer treatments. If you have low platelets due to chemo, radiation, or other therapies, this may offer a new option.
This trial tests a drug called hetrombopag to see if it can prevent low platelet counts caused by antibody-drug conjugate (ADC) chemotherapy in breast cancer patients. It may help you avoid treatment delays or dose reductions.
This trial tests a medication called Herombopag to raise platelet counts in adults aged 60 or older with immune thrombocytopenia (ITP). The goal is to see if it is safe and effective for this age group.
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.